Company Analysis
Sign in

Relay Therapeutics, Inc. (RLAY)

Nasdaq: RLAY · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 2020
Full chart Alerts Compare
Grade5.5
◀ Past 4.7● Present 6.6▶ Future 5.2
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

12 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Relay Therapeutics, Inc.’s names, not what it holds today.

Patents granted
12
12 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 4 in 2024 and 4 in 2023
Applications published
24
6 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry8
Pharmaceuticals4
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Relay Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
24 published
Relay Therapeutics, Inc. its own name
US, as the owner printed on each patent
12 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jun 17, 202512,331,056SHP2 phosphatase inhibitors and methods of use thereofOrganic fine chemistryRelay Therapeutics, Inc.
Feb 4, 202512,219,327Substituted isoindolines as PI3K-alpha inhibitorsOrganic fine chemistryRelay Therapeutics, Inc.
Nov 26, 202412,152,034FGFR inhibitors and methods of making and using the sameOrganic fine chemistryRelay Therapeutics, Inc.
Nov 12, 202412,138,263Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereofPharmaceuticalsRelay Therapeutics, Inc.
Sep 10, 202412,084,447SHP2 phosphatase inhibitors and methods of use thereofOrganic fine chemistryRelay Therapeutics, Inc.
Feb 6, 202411,890,281SHP2 phosphatase inhibitors and methods of making and using the sameOrganic fine chemistryRelay Therapeutics, Inc.
Oct 10, 202311,780,845FGFR inhibitors and methods of use thereofOrganic fine chemistryRelay Therapeutics, Inc.
Jul 18, 202311,701,354Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitorsPharmaceuticalsRelay Therapeutics, Inc.
Apr 18, 202311,629,145SHP2 phosphatase inhibitors and methods of use thereofOrganic fine chemistryRelay Therapeutics, Inc.
Feb 28, 202311,591,336Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitorsPharmaceuticalsRelay Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388565ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOFOrganic fine chemistryRelay Therapeutics, Inc.
Oct 9, 20252025/0313524PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOFOrganic fine chemistryRelay Therapeutics, Inc.
Jul 31, 20252025/0243204FGFR INHIBITORS AND METHODS OF MAKING AND USING THE SAMEOrganic fine chemistryRelay Therapeutics, Inc.
Mar 20, 20252025/0090540PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOFOrganic fine chemistryRelay Therapeutics, Inc.
Mar 13, 20252025/0084048PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOFOrganic fine chemistryRelay Therapeutics, Inc.
Jan 16, 20252025/0019380PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOFPharmaceuticalsRelay Therapeutics, Inc.
Nov 7, 20242024/0368122JAK2 INHIBITORS AND METHODS OF USE THEREOFOrganic fine chemistryRelay Therapeutics, Inc.
Aug 29, 20242024/0287058PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOFOrganic fine chemistryRelay Therapeutics, Inc.
Jun 13, 20242024/0190855CDK INHIBITORS AND METHODS OF USE THEREOFOrganic fine chemistryRelay Therapeutics, Inc.
Apr 18, 20242024/0122925SHP2 PHOSPHATASE INHIBITORS AND METHODS OF MAKING AND USING THE SAMEOrganic fine chemistryRelay Therapeutics, Inc.
What it applied for, 2024 to 2025: Organic fine chemistry 9 · Pharmaceuticals 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton RLAY · research, not advice